Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 5/20 | 0.40 |
| ▸ | NPY4R | P50391 | 9/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.39 |
| ▸ | NPY1R | P25929 | 7/20 | 0.39 |
| ▸ | NPY2R | P49146 | 5/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850341 | 0.93 | FURIN (0.40) | FURINNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6850333 | 0.93 | FURIN (0.40) | FURINNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29485116 | 0.92 | NPY4R (0.38) | NPY4RNPY5RNPY1RNPY2RSLC15A2 | |
| SCHEMBL30087255 | 0.92 | FURIN (0.43) | FURINNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31665959 | 0.91 | NMT2 (0.41) | FURINNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29485106 | 0.91 | NPY4R (0.43) | FURINNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29539785 | 0.91 | NPY4R (0.38) | FURINNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29385639 | 0.90 | C3AR1 (0.45) | FURINSLC15A2NOD1CPB2C3AR1 | |
| SCHEMBL29485113 | 0.90 | ENPEP (0.43) | — | |
| SCHEMBL7206555 | 0.88 | FURIN (0.44) | FURINNPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| CN-120005928-A | Dynamic regulation and control system, strain, construction method of strain and application of strain in microbial fuel cell | 天津科技大学 | 2025-05-16 | — | — | CN | disclosed |
| WO-2024163874-A2 | STABLE AND CONTROLLED RELEASE FORMULATIONS OF NEUREGULIN-4 ANALOGS | AVEXEGEN THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2023-11-23 | — | — | US | disclosed |
| EP-4213886-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | Araris Biotech AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| CN-116406302-A | Method of transglutaminase conjugation with amino acid based linkers | 阿拉里斯生物技术股份公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2022058594-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | SP1, GLUL, TGM2 | FURIN 2592/4885NPY4R 2029/4885NPY5R 2368/4885 |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | FURIN 6/4885NPY4R 1087/4885NPY5R 1326/4885 |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | MYD88, ICOS, CD4 | FURIN 16/4885NPY4R 807/4885NPY5R 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.